Jan 28, 2026 04:01PM
Jan 12, 2026 07:04AM
Jan 12, 2026 07:00AM
Dec 24, 2025 06:00AM
Dec 24, 2025 06:00AM
Dec 6, 2025 09:30AM
Dec 6, 2025 09:30AM Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at
Oct 28, 2025 06:42AM
Oct 22, 2025 07:28AM
Oct 22, 2025 06:00AM
Sep 17, 2025 07:01AM
Sep 17, 2025 07:00AM
Jul 9, 2025 04:01PM
Jul 7, 2025 07:00AM European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
Apr 17, 2025 07:01AM
Apr 17, 2025 07:00AM
Apr 9, 2025 07:05AM
Apr 8, 2025 04:00PM
Mar 17, 2025 07:01AM
Mar 17, 2025 07:00AM
Jan 28, 2025 04:00PM Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
Jan 13, 2025 07:00AM
Dec 22, 2024 04:00AM
Dec 21, 2024 10:00AM
Dec 19, 2024 07:01AM
Dec 19, 2024 07:00AM
Oct 11, 2024 04:00PM
Jul 12, 2024 07:13AM Nurix (NRIX) PT Lowered to $29 at Needham
Jul 11, 2024 04:00PM
Apr 10, 2024 07:00AM
Mar 11, 2024 07:01AM
Mar 11, 2024 07:00AM
Feb 15, 2024 04:00PM
Jan 16, 2024 04:01PM
Jan 16, 2024 04:01PM Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL
Jan 8, 2024 07:02AM
Jan 8, 2024 07:00AM
Nov 1, 2023 04:01PM
Nov 1, 2023 04:01PM
Oct 12, 2023 04:01PM
Jul 13, 2023 04:01PM
Apr 13, 2023 04:01PM Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
Feb 9, 2023 04:15PM
Jan 9, 2023 08:36AM
Jan 9, 2023 08:35AM
Dec 15, 2022 04:02PM
Dec 15, 2022 04:01PM
Nov 10, 2022 09:00AM
Jul 7, 2022 04:05PM Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update
Jun 30, 2022 08:03AM

322,242 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All